Results 231 to 240 of about 56,186 (320)

Real-world clinical outcomes associated with first-line palbociclib and aromatase inhibitor therapy among patients with HR+/HER2- advanced breast cancer in Europe. [PDF]

Breast Cancer Res Treat
Oikonomidou O, Beresford MJ, Galve-Calvo E, Woeckel A, Parikh RC, Hitchens A, Chen C, Doan J, Li B, Ansquer VD, Frugier G, Jimenez MI, Davis KL, Broughton EI.   +13 more
europepmc   +1 more source

Prevalence of Bone Fractures in Women with Breast Cancer: A Systematic Review of the Impact of the Use of Aromatase Inhibitors

Adriele Godgienski, Emanuela Lando, Júlia Pastorello, Rosana Martins   +3 more
openalex   +2 more sources

The Risk of Cardiovascular Disease following Aromatase Inhibitor Therapy for Breast Cancer in Postmenopausal Women: A Systematic Review and Meta-Analysis. [PDF]

Breast Care (Basel)
Berbari E, Anees A, Kaur R, Ayeni FE, Edirimanne S.   +4 more
europepmc   +1 more source

Effects of the efficacy of the <i>Yi Shen Tiao Gan</i> formula on aromatase inhibitor associated musculoskeletal syndrome: a randomized controlled trial. [PDF]

Front Pharmacol
Zhang Y, Chu M, Ye M, Cheng Y, Cong H, Yin Y, Chen H.   +6 more
europepmc   +1 more source

Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival. [PDF]

ESMO Open
Crown J, Stroyakovskii D, Yardley DA, Huang CS, Fasching PA, Bardia A, Chia S, Im SA, Martin M, Xu B, Barrios CH, Untch M, Moroose R, Hurvitz SA, Hortobagyi GN, Slamon DJ, Visco F, Spera G, Zarate JP, Halligan D, Li Z, Loi S.   +21 more
europepmc   +1 more source

Uso de inibidores da aromatase no tratamento do câncer de mama e osteoporose = The use of aromatase inhibitors for breast cancer treatment and osteoporosis

, 2005
Lina Barbosa Cassol, Bernardo Garicochea
openalex   +1 more source

Endocrine disruption induced by organotin compounds; organotins function as a powerful agonist for nuclear receptors rather than an aromatase inhibitor

, 2008
Tsuyoshi Nakanishi
openalex   +2 more sources

Adult Height Following Prepubertal Treatment With Antiandrogen, Aromatase Inhibitor, and Reduced Hydrocortisone in CAH.

J Clin Endocrinol Metab
Merke DP, Mallappa A, Parker M, Sukin C, Kulkarni SE, Keil MF, Van Ryzin C, Hill SC, Reynolds JC, Cutler GB, Sinaii N.   +10 more
europepmc   +1 more source